Bispecific antibodies (BsAbs) are redefining the landscape of therapeutic design, offering dual-target precision that conventional antibodies can’t match. These specially engineered antibodies bind to either two different antigens or two distinct sites on the same antigen. BsAbs form a powerful new class of therapy which has caused excitement among the drug development community due to… The post Bispecific antibodies: The next generation of precision therapeutics appeared first on Drug ...| Drug Discovery and Development
Nektar Therapeutics stock skyrocketed 287% after rezpegaldesleukin hit all endpoints in atopic dermatitis trials, but ongoing litigation with Lilly could complicate matters.| Drug Discovery and Development
In April 2023, I received a letter from the Ontario government with information about the new biosimilar switching policy. I had until the end of the year to switch from the biologic medication I take to treat my rheumatoid arthritis (RA) to a biosimilar. I did my best to be hopeful and believe it would…| The Seated View
In March 2023, I received a letter from the Ontario government. It informed me that a biosimilar switching policy was now in place. People like me who receive funding from the government to pay for Biologics for rheumatoid arthritis (RA), Crohn’s disease, and other forms of autoimmune disease were given until the end of 2023…| The Seated View
The phase 4 EVEREST study showed that Dupixent demonstrated superiority over Xolair in adults with chronic rhinosinusitis.| Drug Discovery and Development
The FDA has approved ENFLONSIA for the prevention of RSV lower respiratory tract disease in infants and newborns.| Drug Discovery and Development
Just over three-quarters of patients receiving Sanofi and Regeneron’s Dupixent achieved at least a 75% improvement in disease severity.| Drug Discovery and Development
Learning that a biologic medicine hasn’t worked for you is hard. Being told that you have “failed” that medicine is worse. Let’s change that narrative. You didn’t fail. The medicine failed you.| CreakyJoints Australia
Were you affected by the abatacept (Orencia®) shortage this year? If so, we have great news. The supply situation in Australia has improved and you may be able to return to your previous treatment regime.| CreakyJoints Australia